Press Release
Panacea Biotec Ltd. is pleased to announce that it has entered into Joint Collaboration for Development, License, Manufacturing, Supply and Sales of 7 complex generic pharmaceutical products with Bionpharma Inc., a generic pharmaceutical company based in the United States. Shareholding for the Period Ended June 30, 2017
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click here Statements Of Investor Complaints For The Quarter Ended 30Th June,2017
Quarterly Report of investor complaints under Regulation 13 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 for the quarter ending June 30, 2017 Updates
Corrigendum of Audited Financial Results (Standalone and consolidated) for the quarter / year ended 31st March, 2017. Financial Results For March 31, 2017
Audited Financial Results (Standalone and Consolidated) for the Quarter / Year ended 31st March, 2017 Passing over of Dividend for the financial year 2016-17 May 30,2017
Intimation of postponement of Board Meeting for approving the Audited Financial Results For the Quarter/ Financial Year ended 31st March, 2017 Closure of Trading Window
Pursuant to the provisions of Regulations 30 & 51 of the SEBI (LODR) Regulations, the trading window of the Company shall remain closed for all designated persons including promoters, directors, key managerial personnel and designated employees of the Company from 16th May, 2017 and will reopen 48 hours after the results for the Quarter / Financial Year ended 31st March, 2017 are made public in accordance with the SEBI (Prohibition of Insider Trading)... Board Meeting On 26Th May, 2017
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 {'SEBI (LODR) Regulations'}, this is to inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on Friday, 26th May, 2017 at New Delhi to, inter-alia, consider and approve the Audited Financial Results for the Quarter / Financial Year ended 31st March, 2017. Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 For Half-Year Ended 31St March, 2017
Pursuant to the provisions of Regulation 40(10) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we are enclosing herewith the certified copy of certificate from M/s R & D, Company Secretaries, for the half-year ended 31st March, 2017, confirming that all the transfers of shares have been completed within the stipulated time.